Skip to main content

Government Funding Lapse
Because of a lapse in government funding, the information on this website may not be up to date, transactions submitted via the website may not be processed, and the agency may not be able to respond to inquiries until appropriations are enacted.

The NIH Clinical Center (the research hospital of NIH) is open. For more details about its operating status, please visit cc.nih.gov.

Updates regarding government operating status and resumption of normal operations can be found at opm.gov.

Clinical Trials Using Regorafenib

Review the clinical trials studying regorafenib on this list and use the filters to refine the results by age and location. Some clinical trials are held at NCI-Designated Cancer Centers and may be supported by other organizations.

You can find more information about the types and phases of clinical trials and what to expect or use our Steps to Find a Clinical Trial.

Trials 1-11 of 11

A Trial to Evaluate Multiple Regimens in Newly Diagnosed and Recurrent Glioblastoma
Status: Active
Location: 30 locations
TAPUR: Testing the Use of Food and Drug Administration (FDA) Approved Drugs That Target a Specific Abnormality in a Tumor Gene in People With Advanced Stage Cancer
Status: Active
Location: 16 locations
Regorafenib for the Treatment of Specific Gastrointestinal Stromal Tumors Mutation Subsets
Status: Active
Location: M D Anderson Cancer Center, Houston, Texas
Regorafenib Combined with Fulvestrant for the Treatment of Recurrent Low-Grade Serous Ovarian Cancer
Status: Active
Location: Case Comprehensive Cancer Center, Cleveland, Ohio
Regorafenib in Combination with Pembrolizumab or Pembrolizumab Alone for the Treatment of Metastatic or Unresectable MSI-H Colorectal Cancer
Status: Active
Location: University of Pittsburgh Cancer Institute (UPCI), Pittsburgh, Pennsylvania
Regorafenib and Yttrium-90 Transarterial Radioembolization for the Treatment of Unresectable Hepatocellular Cancer
Status: Active
Location: University of Miami Miller School of Medicine-Sylvester Cancer Center, Miami, Florida
Sunitinib and Regorafenib for the Treatment of Patients with Metastatic or Unresectable Gastrointestinal Stromal Tumors and KIT Gene Mutations
Status: Active
Location: University of Miami Miller School of Medicine-Sylvester Cancer Center, Miami, Florida
Regorafenib and Durvalumab for the treatment of Unresectable or Metastatic Biliary Tract Cancer
Status: Active
Location: University of Kansas Cancer Center, Kansas City, Kansas
Safety and Efficacy of NEO212 in Patients with Astrocytoma IDH-mutant, Glioblastoma IDH-wildtype or Brain Metastasis
Status: Active
Location: USC / Norris Comprehensive Cancer Center, Los Angeles, California
Regorafenib in Combination with Venetoclax and Azacitidine for the Treatment of Patients with Relapsed or Refractory Acute Myeloid Leukemia
Status: Active
Location: City of Hope Comprehensive Cancer Center, Duarte, California
Testing a New Combination of Anti-cancer Drugs in Patients Newly Diagnosed with Ewing Sarcoma Who Have Cancer That Has Spread to Other Parts of the Body
Status: Approved
Location: Location information is not yet available.